Weight-Loss Drug's Benefits And Risks Revealed in New Study

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...